VANQUISH 1: VK2735 Phase 3 trial (NCT07104500)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants Without Type 2 Diabetes Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition
Registry record checked
At a glance
- Phase
- Phase 3
- Status
- Active, not recruiting
- Enrolment
- 4,500
- estimated
- Start
- 23 Jun 2025 (actual)
- Primary completion
- 1 Jul 2027 (estimated)
- Sponsor
- Viking Therapeutics, Inc.
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Placebo Assignment | Placebo comparator | Drug: VK2735 | VK2735 Placebo Comparator Once Weekly |
| Active Assignment (Dose 1) | Experimental | Drug: VK2735 | VK2735 7.5mg Once Weekly |
| Active Assignment (Dose 2) | Experimental | Drug: VK2735 | VK2735 12.5mg Once Weekly |
| Active Assignment (Dose 3) | Experimental | Drug: VK2735 | VK2735 17.5mg Once Weekly |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment | 78 Weeks |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Percentage of participants who achieve ≥5%, ≥10%, ≥15% and ≥20% body weight reduction after 78 weeks of treatment | 78 Weeks |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants Without Type 2 Diabetes Who Are Obese, or Overweight With at Least One Weight-related Comorbid ConditionClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.